Breast Cancer
Conditions
Brief summary
Nearly 200 cases are to be enrolled. The information of patient age, histologic grade, tumor size, ER and PR status, Ki-67 index, surgery mode should be provided. The adjuvant therapy regime (chemotherapy: none, TC\*4, TC\*6 or EC-T; endocrine therapy: TAM, OFS+TAM, OFS+AI) will be compared before and after MammaPrint testing. About 20 clinical staffs are enrolled to participate in this survey for the clinical decision making. Each case could be chosen five times at random.
Interventions
None listed
Sponsors
Study design
Eligibility
Inclusion criteria
1. pre-menopausal breast cancer patients aged less than 50 years old. 2. Pathology confirmed invasive dutal carcinoma or invasive lobular carcinoma. 3. receiving breast conserving surgery or mastectomy with/without reconstruction; sentinel lymph node biopsy or axillary lymph node dissection. 4. TNM staging: T1b-T2N0-1M0. 5. molecular subtype: ER positive/HER2 negative. 6. MammaPrint testing before initiation of adjuvant therapy.
Exclusion criteria
1. Incomplete medical history. 2. Pregnancy or lactation. 3. Contradiction of chemotherapy or ovarian function suppression.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Treatment decision survey | 6 weeks | Treatment decision change after MammaPrint testing |
Countries
China